Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.

Leukemia - 1 Jun 2008

Sherbenou D W, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press R D, Superti-Furga G, Druker B J, Deininger M W

Abstract excerpt

The BCR-ABL oncogenic tyrosine kinase causes chronic myeloid leukemia and is the target for imatinib therapy. During imatinib treatment, cells are selected in some patients with BCR-ABL kinase domain mutations that render decreased drug sensitivity. In addition, some patients express deletion mutants of BCR-ABL, apparently due to missplicing. Most commonly these deletion mutants lack a significant portion of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Precursor Cells, B-Lymphoid

Share to Pyrimidines

Share to Tyrosine

Source

Identifiers

PMID: 18354488
DOI: 10.1038/leu.2008.65

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.PMID 18354488Read ↗

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemiaSemantic proximity Read ↗

A common phosphotyrosine signature for the Bcr-Abl kinaseSemantic proximity Read ↗

Re-evaluating the role of BCR/ABL in chronic myelogenous leukemiaSemantic proximity Read ↗

Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.Semantic proximity Read ↗

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.Semantic proximity Read ↗

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.Semantic proximity Read ↗

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.Semantic proximity Read ↗

The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.Semantic proximity Read ↗

Genetic approaches to defining signaling by the CML-associated tyrosine kinase BCR-ABL.Semantic proximity Read ↗

Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors.Semantic proximity Read ↗

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.Semantic proximity Read ↗

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinibSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.